CSIMarket Company Name, Ticker, Competitors, else..
 
Axim Biotechnologies Inc   (AXIM)
Other Ticker:  
 
 
Price: $0.0031 $0.00 -3.125%
Day's High: $0.0047 Week Perf: 82.35 %
Day's Low: $ 0.00 30 Day Perf: 72.22 %
Volume (M): 412 52 Wk High: $ 0.02
Volume (M$): $ 1 52 Wk Avg: $0.01
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 227
 Employees 45
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Axim Biotechnologies Inc
Axim Biotechnologies Inc is a biotechnology company that specializes in the development of pharmaceutical and nutraceutical products. The company focuses on utilizing cannabinoid compounds for various medicinal purposes. Axim Biotechnologies conducts research, development, and clinical trials to create innovative therapies and treatments for conditions such as multiple sclerosis, irritable bowel syndrome, psoriasis, and opioid addiction. The company's goal is to provide safe and effective solutions for patients through the use of cannabinoids.


   Company Address: 6191 Cornerstone Court San Diego 92121 CA
   Company Phone Number: 923-4422   Stock Exchange / Ticker: AXIM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
GBLX      % 
IIPR      % 
TLRY      % 
• View Complete Report
   



Axim Biotechnologies Inc

Pharmaceutical Giant Skyrockets Revenue by 616% in Recent Fiscal Period

Axim Biotechnologies Inc: Revolutionizing Healthcare through Innovation
In the fast-paced and ever-evolving field of healthcare, biotech companies are continually striving to innovate and improve patient outcomes. Axim Biotechnologies, a ground-breaking pharmaceutical company, has recently presented groundbreaking research and development initiatives at the Benzinga Virtual Healthcare Summit 2024. This article aims to interpret the key findings and implications from two articles, one highlighting Axim Biotechnologies CEO John Huemoeller II's presentation, and another showcasing his interview on the company's diagnostic research programs in Dry Eye Disease and Parkinson's Disease. Additionally, the impact of these developments on Axim Biotechnologies will be evaluated.
Axim Biotechnologies, an industry leader in medical innovation, has captured the attention of industry professionals and investors alike with its cutting-edge research and development initiatives. In his presentation at the Benzinga Virtual Healthcare Summit 2024, Axim Biotechnologies CEO, John Huemoeller II, shed light on the company's ongoing endeavors aimed at revolutionizing the diagnosis and treatment of complex medical conditions. Leveraging cutting-edge technologies and scientific advancements, Axim Biotechnologies is poised to bring about groundbreaking changes in the field.
Product Service News

Pioneering Diagnostic Research Programs in Dry Eye Disease and Parkinson's Disease: Axim Biotechnologies Steers Ahead

Published Wed, Mar 27 2024 1:01 PM UTC

In the fast-paced and ever-evolving field of healthcare, biotech companies are continually striving to innovate and improve patient outcomes. Axim Biotechnologies, a ground-breaking pharmaceutical company, has recently presented groundbreaking research and development initiatives at the Benzinga Virtual Healthcare Summit 2024. This article aims to interpret the key findings ...
Partnership

Scaling Up Diagnostic Tools: AXIM Biotechnologies Joins Hands with Auer Precision to Amplify Assay Production

Published Wed, Dec 20 2023 2:00 PM UTC

Biotech company AXIM Biotechnologies has entered into a critical partnership with a leading diagnostic manufacturer, Auer Precision, to scale up the production of diagnostic assays for testing Immunoglobulin E (IgE) and Lactoferrin DED, marking a significant milestone in the evolution of the diagnostic healthcare industry.AXIM Biotechnologies, fervently dedicated to amplifyi...
Axim Biotechnologies Inc

Axim Biotechnologies Inc Shatters Expectations with Record-Breaking Numbers for Fiscal Q3 2023

Axim Biotechnologies Inc, a leading player in the biotech industry, has showcased impressive performance in the fiscal third quarter of 2023. While many businesses in the Major Pharmaceutical Preparations sector have struggled with dwindling revenues and diminishing top-line, Axim Biotechnologies Inc has managed to achieve a remarkable turnaround.
The company reported balanced books in the fiscal third quarter of 2023, with earnings per share reaching $0.00. This is a significant improvement compared to the previous year's figure of $-0.01 per share and indicates a positive trend for the company. Additionally, the company demonstrated growth in terms of revenue, with a sharp increase to $0.01 million from $0.00 million in the corresponding reporting season a year before.
Axim Biotechnologies Inc

Axim Biotechnologies Inc Surprises Market with Revenue of $0.009929 Million, but Faces Mounting Net Shortfall of $-3.723 Million

Axim Biotechnologies Inc is a biotechnology company that recently reported a revenue of $0.009929 million in the second quarter of 2023. Despite this positive revenue, the company experienced a net shortfall of $-3.723 million, which is higher compared to $-1.223 million in the same period last year.
This significant increase in net shortfall is a concerning factor for Axim Biotechnologies Inc. However, it is important to note that financial results can fluctuate throughout the year, and it is possible that the company can make improvements in the future. Investors will need to keep a close eye on the company's financial performance to assess if these shortfalls continue or if the company can recover in upcoming quarters.






Axim Biotechnologies Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com